Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Liver Transpl. 2019 08; 25(8):1155-1164.
View in:
PubMed
subject areas
Biomarkers
Double-Blind Method
Echocardiography
Female
Hepatopulmonary Syndrome
Humans
Male
Middle Aged
Neovascularization, Pathologic
Placebos
Proof of Concept Study
Protein Kinase Inhibitors
Quality of Life
Treatment Outcome
authors with profiles
David G Koch